Saturday, September 15, 2018 -- A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins cholesterol could be a cost-effective intervention for patients at high risk of cardiovascular disease, according to new research led by Harvard T.H. Chan School of Public Health.
Thursday, September 20, 2018 -- OBJECTIVE Elevated LDL cholesterol (LDLc) is not strongly associated with obesity or metabolic syndrome (MS), but this relationship repeatedly has been examined assuming a linear association. This study aimed to assess the dose-response relationship between body mass index (BMI) or waist circumference (WC) and LDLc and to evaluate its link to metabolic impairment. RESEARCH DESIGN AND METHODS Participants in the continuous National Health and Nutrition Examination Survey (NHANES, 1999–2010) (n = 12,383) and the Study on Nutrition and Cardiovascular Risk (ENRICA, 2008–2010) (n = 11,765), representative samples of U.S. and Spanish noninstitutionalized populations, were cross-sectionally investigated. LDLc was modeled with age- and sex-adjusted regressions, with BMI and/or WC as explanatory variables included in models as two-segment linear and natural
Thursday, September 20, 2018 -- MedicalResearch.com Interview with: Luca A. Lotta, MD, PhD Senior Clinical Investigator MRC Epidemiology Unit University of Cambridge MedicalResearch.com: What is the background for this study? What are the main findings? Drugs that enhance the breakdown of circulating triglycerides by activating … Continue reading →